These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

399 related items for PubMed ID: 10390227

  • 1. Single-dose pharmacokinetics and safety of abacavir (1592U89), zidovudine, and lamivudine administered alone and in combination in adults with human immunodeficiency virus infection.
    Wang LH, Chittick GE, McDowell JA.
    Antimicrob Agents Chemother; 1999 Jul; 43(7):1708-15. PubMed ID: 10390227
    [Abstract] [Full Text] [Related]

  • 2. A comparison of the steady-state pharmacokinetics and safety of abacavir, lamivudine, and zidovudine taken as a triple combination tablet and as abacavir plus a lamivudine-zidovudine double combination tablet by HIV-1-infected adults.
    Crémieux AC, Katlama C, Gillotin C, Demarles D, Yuen GJ, Raffi F, AZl10002 Study Group.
    Pharmacotherapy; 2001 Apr; 21(4):424-30. PubMed ID: 11310515
    [Abstract] [Full Text] [Related]

  • 3. Abacavir/lamivudine/zidovudine as a combined formulation tablet: bioequivalence compared with each component administered concurrently and the effect of food on absorption.
    Yuen GJ, Lou Y, Thompson NF, Otto VR, Allsup TL, Mahony WB, Hutman HW.
    J Clin Pharmacol; 2001 Mar; 41(3):277-88. PubMed ID: 11269568
    [Abstract] [Full Text] [Related]

  • 4. A randomized, double-blind study of triple nucleoside therapy of abacavir, lamivudine, and zidovudine versus lamivudine and zidovudine in previously treated human immunodeficiency virus type 1-infected children. The CNAA3006 Study Team.
    Sáez-Llorens X, Nelson RP, Emmanuel P, Wiznia A, Mitchell C, Church JA, Sleasman J, Van Dyke R, Richardson CG, Cutrell A, Spreen W, Hetherington S.
    Pediatrics; 2001 Jan; 107(1):E4. PubMed ID: 11134468
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
    Vourvahis M, Davis J, Langdon G, Layton G, Fang J, Choo HW, Hansson AG, Tawadrous M.
    Antivir Ther; 2013 Jan; 18(6):745-54. PubMed ID: 23558061
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
    Sprenger HG, Langebeek N, Mulder PG, Ten Napel CH, Vriesendorp R, Hoepelman AI, Legrand JC, Koopmans PP, Bravenboer B, Ten Kate RW, Groeneveld P, Bierman W, van der Werf Ts, Gisolf E, Richter C.
    HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
    [Abstract] [Full Text] [Related]

  • 13. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania.
    Shao HJ, Crump JA, Ramadhani HO, Uiso LO, Ole-Nguyaine S, Moon AM, Kiwera RA, Woods CW, Shao JF, Bartlett JA, Thielman NM.
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1277-85. PubMed ID: 20001518
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Lopinavir/ritonavir plus lamivudine and abacavir or zidovudine dose ratios for paediatric fixed-dose combinations.
    Bouazza N, Foissac F, Fauchet F, Burger D, Kiechel JR, Treluyer JM, Capparelli EV, Lallemant M, Urien S.
    Antivir Ther; 2015 Dec; 20(2):225-33. PubMed ID: 25279808
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Population pharmacokinetics and pharmacodynamic modeling of abacavir (1592U89) from a dose-ranging, double-blind, randomized monotherapy trial with human immunodeficiency virus-infected subjects.
    Weller S, Radomski KM, Lou Y, Stein DS.
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2052-60. PubMed ID: 10898675
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.